Tag Archives: CS1

Second Multiple Myeloma Antibody Approved – Empliciti

Elotuzumab (Empliciti) is now the second monoclonal antibody (Mab) approved by the FDA for multiple myeloma (MM). Darzalex (daratumumab), the first Mab for MM, was approved by the FDA just 3 weeks ago. Continue reading

Elotuzumab plus Revlimed and Dexamethasone in Multiple Myeloma

In the Phase III ELOQUENT-2 study, patients receiving elotuzumab plus standard therapy compared with patients receiving standard therapy alone, lived a median time of 19.4 months until their disease progressed or until they died, compared with 14.9 months in those who received standard therapy alone. In addition, at a median follow-up period of two years, elotuzumab reduced the risk of disease progression or death by 30 percent. Continue reading